| Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies. Co.'s lead candidate, AFM13, is an innate cell engager designed for the treatment of certain CD30-positive (CD30+) B- and T cell malignancies. Co.'s second clinical stage candidate, AFM11, is a T cell engager designed for the treatment of certain CD19+ B cell malignancies, including non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia. Co.'s third candidate, AFM24, is an innate cell-engaging bispecific antibody targeting EGFR. Co. has also developed AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen to treat multiple myeloma. The AFMD YTD return is shown above.
The YTD Return on the AFMD YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AFMD YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AFMD YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.